FDA eases outsourcing facility ibuprofen compounding for hospitals
To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms, the Food and Drug Administration Friday released for outsourcing facilities compounding certain ibuprofen oral suspension products.
鈥淎lthough FDA is monitoring the global pharmaceutical supply chain and working, within its authorities, with manufacturers of approved ibuprofen oral suspension products, to bolster supply, temporary flexibility is needed to help ensure that treatment options are available to hospitals and health systems during this period of increased demand,鈥 the guidance states.
Related News Articles
Headline
President Trump April 9 announced that reciprocal tariffs that went into effect after midnight for certain nations will be paused for 90 days, while tariffs鈥
Headline
The Food and Drug Administration March 14 released a notice on a nationwide shortage of hemodialysis tubes expected to last through early fall. On Jan. 8, B.鈥
Headline
The AHA late Feb. 4 told the administration that its current and proposed tariffs on Canada, Mexico and China may jeopardize the availability of vital鈥
Headline
Baxter Jan. 28 announced that IV solutions production has been restarted on all manufacturing lines at its North Carolina site impacted by Hurricane Helene in鈥
Headline
Baxter notified customers on Jan. 22 that allocations for two sodium chloride IV solutions have been increased to 100%. According to Baxter, the products will鈥
Headline
After incurring damage from Hurricane Helene on Sept. 27, Baxter reports that as of Dec. 19, nearly all of its manufacturing lines in its North Cove, N.C鈥